Physician profile
Christopher Robert Dangelo
NPI 1629416409
$60,283.52
in general payments reported to CMS, 2019-2025
20 companies · $19K in 2025
The $19K reported for 2025 was more than what 83% of Hematology (Internal Medicine) providers received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,205 · 2022: $13K · 2023: $13K · 2024: $12K · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $24K · Honoraria: $14K · Travel and Lodging: $3,933 · Food and Beverage: $2,499 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $454.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $23,706.17 |
| Honoraria | $13,500.00 |
| Travel and Lodging | $3,932.77 |
| Food and Beverage | $2,499.27 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $453.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $18,957.89 | 2021-2023 | Adcetris |
| Adc Therapeutics America, INC. | $15,108.85 | 2024-2025 | |
| Abbvie INC. | $7,693.18 | 2022-2025 | Venclexta |
| E.R. Squibb & Sons, L.L.C. | $6,251.94 | 2022-2024 | |
| Genmab U.S., INC. | $4,483.72 | 2024 | Epkinly |
| Tg Therapeutics, INC. | $3,074.74 | 2021 | |
| Beigene USA, INC. | $2,291.21 | 2023-2024 | Brukinsa |
| Astrazeneca Pharmaceuticals LP | $863.36 | 2022-2024 | |
| Abbott Laboratories | $478.14 | 2025 | Aveir |
| Celgene Corporation | $399.07 | 2022-2025 | Breyanzi |
| Taiho Oncology, INC. | $260.75 | 2024 | |
| Genentech USA, INC. | $171.42 | 2023-2024 | |
| Beone Medicines USA, INC. | $111.36 | 2025 | Brukinsa |
| Pfizer INC. | $104.09 | 2023 | |
| Kyowa Kirin, INC. | $33.80 | 2022 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Dangelo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.